HAHasan Açık

Hasan Açık

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article


Hasan Açık has a total of 10 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Perceived Stress and Irritable Bowel Syndrome–Compatible Symptoms Among Turkish Medical Students Without a Prior Diagnosis: A Cross-Sectional Study

    by Hasan Açık

    Objective: To estimate the frequency of symptoms compatible with the Rome IV criteria for irritable bowel syndrome (IBS) and examine their association with perceived stress among Turkish medical students without a prior physician-confirmed IBS diagnosis. Methods: This cross-sectional online survey evaluated 1100 Turkish medical students from June to July 2026. Participation was voluntary. Students with a prior physician-confirmed IBS diagnosis were excluded. Data collected anonymously included demographics, lifestyle, Rome IV-based symptoms, and the 10-item Perceived Stress Scale (PSS-10). Results: Out of 362 respondents, 54 with prior IBS and 34 with incomplete surveys were excluded, leaving 274 students in the analytic sample. Forty-two students met the criteria for IBS compatibility (15.3%). No significant differences were identified for sex, smoking, coffee intake, exercise, body mass index, or academic year. Energy drink consumption showed an overall association with symptoms (P = .03). Symptom prevalence varied across perceived stress categories (overall P = .02); however, the crude high- vs low-stress comparison was imprecise (OR, 4.00; 95% CI, 0.80-20.04). In multivariable analysis, each 1-point increase in PSS-10 score was associated with greater adjusted odds of IBS-compatible symptoms (aOR, 1.09; 95% CI, 1.03-1.15; P = .003). Energy drink use at least once weekly was also independently associated with higher adjusted odds of symptoms (aOR, 2.41; 95% CI, 1.06-5.48; P = .04). Conclusion: IBS-compatible symptoms were reported by 15.3% of medical students without a prior diagnosis. Higher perceived stress and weekly energy drink use were independently associated with symptom status. Prospective multicenter studies are needed to establish temporality.

  • Open Access

    Persistence of Gastric Atrophy and Intestinal Metaplasia Six Months After H. pylori Treatment: A Retrospective Cohort Study

    by Hasan Açık, Kağan Gökçe

    Objective: To assess the persistence and regression of gastric atrophy and intestinal metaplasia (IM) approximately six months after Helicobacter pylori treatment in patients undergoing repeat gastric biopsy.Methods: This single-center retrospective cohort included 70 patients with biopsy-confirmed H. pylori infection who received 14-day quadruple therapy and underwent follow-up endoscopy with biopsy approximately six months later. Histological findings were compared with baseline findings.Results: H. pylori was not detected on follow-up histology in 64/70 patients (91.4%). Among patients with baseline lesions, gastric atrophy persisted in 9/13 (69.2%) and IM in 19/21 (90.5%). No new atrophy (0/57) or IM (0/49) was identified among patients without the corresponding baseline lesion.Conclusion: Gastric atrophy and IM remained detectable in most patients with these baseline lesions at six months. Longer follow-up is required to assess regression and treatment effects.

  • Open Access

    The Association of microRNA-145 and microRNA-191 with Therapeutic Response in Patients with Inflammatory Bowel Disease

    by Osman Anil Savaş, Hasan Açik, Taner Kivilcim, Amir Mahdi Akbari, Mehrdad Sheikhvatan

    Background: The discovery of non-invasive biomarkers that can predict the therapeutic response in Inflammatory Bowel Disease (IBD) is of utmost importance in the field of personalized medicine. The present prospective cohort study was designed to investigate the use of circulating levels of plasma microRNA-145 (miR-145) and microRNA-191 (miR-191) in the diagnosis and association with therapeutic response in Crohn’s disease (CD) and ulcerative colitis (UC). Methods: The present study was conducted as a retrospective observational cohort study on 183 adult IBD patients, consisting of 96 CD patients and 87 UC patients. Patient data and study parameters were obtained retrospectively from existing clinical records and available laboratory/molecular data collected during routine clinical care. A healthy control group consisting of 92 individuals was included for comparison with the patients with IBD. The circulating levels of miR-145 and miR-191 were assessed in the peripheral blood plasma at baseline using qRT PCR. The clinical response was evaluated at 12 weeks using the CDAI score for CD and the Mayo score for UC. Results: In active IBD, there was significant down-regulation of miR-145 and significant up-regulation of miR-191. Responders at 12 weeks had significantly higher levels of baseline miR-145 (2.0-fold, p < 0.001) and lower levels of miR-191 (1.8-fold, p < 0.001) compared with non-responders. Also, miR-145 negatively correlated with disease activity, and miR-191 positively correlated with acute inflammation markers. ROC curve analysis showed good discriminative values for both miR-145 and miR-191. Conclusions: The level of circulating miR-145 and miR-191 correlates with the activity of IBD. Importantly, the baseline level of miR-145 expression is a non-invasive potential biomarker associated with therapeutic response at 12 weeks.

  • Open Access

    Influenza vaccine hesitancy among healthcare workers in a university hospital in Turkiye: a cross-sectional study

    by Hasan Açik, Servet Öztürk, Amir M Akbari

    Introduction: This study aimed to evaluate influenza vaccine hesitancy among healthcare workers (HCWs) at Istanbul Okan University Hospital and also explore the factors influencing their decision to get the influenza vaccine. Methodology: A cross-sectional questionnaire was conducted with 428 HCWs, and a 94% response rate was achieved. The questionnaire included demographic data, knowledge assessments about influenza, and vaccination history. Results: Only 22% of participants reported receiving the influenza vaccine in 2024, while 78% did not. The main reasons for hesitancy were distrust in vaccine efficacy (32%), fear of side effects (32%), and distrust of vaccine manufacturers (31%). Among those who were vaccinated, the key motivations included self-protection (19%) and being part of a risk group (15%). Interestingly, 91% of respondents had received the coronavirus disease 2019 (COVID-19) vaccine, citing similar reasons for acceptance or refusal. Conclusions: Despite well-documented evidence of the influenza vaccine's role in reducing morbidity and mortality, hesitancy remains prevalent, reflecting certain trends also observed in the literature. Educational and health promotion campaigns, on-site vaccination programs, and awareness initiatives emerged as potential strategies that would improve the vaccine uptake. This study highlights the critical need for targeted interventions to address vaccine hesitancy among HCWs. Building trust, providing accurate information, and ensuring easy access to vaccines are essential steps to boost influenza vaccination rates and enhance public health outcomes.

  • Open Access

    Body Mass Index Does Not Predict High Miller–Payne Response to Neoadjuvant Chemotherapy in Stage II–III Breast Cancer: A Single-Center Retrospective Cohort Study of 647 Patients

    by Hasan Acik, Serdar Arici

    Background: Neoadjuvant chemotherapy (NACT) response in breast cancer is primarily influenced by tumor biology; however, the independent role of host-related factors such as body mass index (BMI) remains unclear. This study evaluated clinicopathological predictors of a high Miller–Payne response after neoadjuvant chemotherapy in patients with stage II–III non-metastatic breast cancer, with particular focus on the role of body mass index. Methods: In this retrospective cohort study, 647 patients with stage II–III non-metastatic breast cancer treated with standard NACT between January 2010 and December 2020 at a single tertiary center were included. High pathological response was defined as Miller–Payne Grades 4–5. Clinical and tumor-related variables were analyzed, including age, menopausal status, body mass index, clinical stage, tumor grade, estrogen receptor status, progesterone receptor status, human epidermal growth factor receptor 2 status, and Ki-67 proliferation index. Univariate and multivariable logistic regression analyses were performed to determine independent predictors of high pathological response. Results: A total of 647 patients were included (mean age: 49.18 ± 10.94 years; mean BMI: 28.45 ± 5.45 kg/m2), of whom 47.45% were postmenopausal. High Miller–Payne response (Grades 4–5) was observed in 40.96% of patients. High response was significantly associated with clinical stage (p = 0.034), tumor grade (p < 0.001), HER2 status (p < 0.001), ER status (p < 0.001), PR status (p < 0.001), and Ki-67 levels (p < 0.001). Median Ki-67 was higher in the high-response group (35.00% [IQR: 20.00–62.75] vs. 25.00% [IQR: 15.00–45.75], p < 0.001). No significant associations were observed for age (p = 0.299), BMI (p = 0.874), or menopausal status (p = 0.289). In multivariable analysis, HER2 positivity (adjusted OR = 3.71, 95% CI: 2.23–6.20, p < 0.001) and Ki-67 (adjusted OR = 1.01 per 1% increase, 95% CI: 1.00–1.02, p = 0.009) were independently associated with high response, whereas ER positivity (adjusted OR = 0.50, 95% CI: 0.25–0.98, p = 0.043) and postmenopausal status (adjusted OR = 0.37, 95% CI: 0.17–0.81, p = 0.013) were inversely associated. BMI was not independently associated with response (p = 0.964). Conclusions: Response to neoadjuvant chemotherapy appears to be mainly determined by tumor biology, particularly receptor status and proliferative activity, rather than anthropometric measures such as body mass index.

  • The Impact of Selenium Deficiency and Supplementation on Hashimoto’s Thyroiditis: A Clinical Evaluation

    by Hasan Acik, Yusuf Aydin

    Introduction: Hashimoto thyroiditis (HT) is an autoimmune disorder that leads to hypothyroidism. Selenium (Se) is essential for thyroid hormone metabolism and immune function, but its role in HT remains debated. This study investigates Se levels in HT patients and evaluates the impact of supplementation on thyroid autoimmunity and thyroid function. Methods: This retrospective study analyzed HT patients and healthy controls. Biochemical parameters, including Se, thyroid-stimulating hormone (TSH), free triiodothyronine (FT3), free thyroxine (FT4), anti-thyroid peroxidase (anti-TPO), and anti-thyroglobulin (anti-Tg) antibodies, were compared. Se-deficient HT patients (<80 µg/L) received selenium supplementation for six months. Paired t-tests and Spearman correlation analyses were used for statistical evaluation Results: Among 270 HT patients and 350 controls, TSH levels were significantly elevated in HT (p<0.001), whereas Se levels showed no significant baseline difference (p=0.87). In Se-deficient patients (n=60), supplementation increased Se levels from 68.60±12.10 µg/L to 104.92±34.45 µg/L (p<0.001). However, anti-TPO and anti-Tg levels increased after treatment (p=0.01 and p=0.03, respectively). No significant changes were observed in TSH (p=0.27), FT3 (p=0.20), or FT4 (p=0.19). Se positively correlated with anti-TPO (r=0.36, p=0.0102) and negatively with FT3 (r=-0.39, p=0.0046). Discussion: Selenium supplementation restored serum Se levels but was unexpectedly associated with increased antibody titers. This finding contrasts with several randomized trials reporting antibody reduction, suggesting that baseline Se status, the form of supplementation, or differences in study design may account for the discrepancy. The observed correlations should be interpreted with caution. Conclusion: Selenium supplementation normalizes selenium status in HT patients, but its effects on thyroid autoimmunity and thyroid function remain uncertain. Long-term randomized controlled trials are needed to determine its therapeutic value.

  • Open Access

    Factors Associated with Post-COVID Syndrome Three Months After COVID-19

    by Hasan Açık, Gülen Açık

    Objective: Post-COVID Syndrome has been defined as a syndrome with chronic fatigue and psychiatric problems continue after COVID-19. In this study, it was aimed to evaluate patients' health-related quality of life standards 3 months after COVID-19 diagnosis. Method: In this study, the psychosocial status and quality of life standards of patients, who were older than 18 years old and followed up due to COVID-19 in the outpatient clinic, ward, or intensive care unit of a university hospital, were assesed by the short form-36 scoring system. Results: Of 67 patients, 57 were followed up and treated at home, nine were admitted to the ward, and one was admitted to the the intensive care unit. Short form-36 test scores of women patients, patients aged over 65, had at least one comorbid disease, and inpatient treatments during acute infection were found to be statistically significantly lower. Conclusion: Gender, advanced age, presence of comorbidity, and history of hospitalization were determined as risk factors for Post-COVID Syndrome.